INmune Bio Secures MHRA Alignment for RDEB Therapy Ebstrocel™
Event summary
- INmune Bio received written alignment from the MHRA on May 12, 2026, supporting its planned 2026 UK Conditional Marketing Authorization Application for Ebstrocel™ in RDEB.
- MHRA recognized MissionEB Phase 2 data as demonstrating clinically meaningful symptomatic benefits, particularly in pain and pruritus.
- The MHRA validated INmune Bio’s CMC and commercial manufacturing framework, non-clinical safety package, and rare-disease clinical evidence framework.
- INmune Bio plans to submit the UK MAA in 2026, with EU and US submissions following in late 2026 or early 2027.
The big picture
INmune Bio’s alignment with the MHRA marks a critical de-risking milestone for its Ebstrocel™ therapy, providing a clear regulatory path for conditional marketing authorization in the UK. This development underscores the growing acceptance of innovative approaches to rare disease treatments, particularly those leveraging cell-based therapies. The strategic context is significant as it positions INmune Bio to potentially become a key player in the treatment of RDEB, an ultra-rare and debilitating condition with limited therapeutic options.
What we're watching
- Regulatory Pathway
- How the MHRA’s alignment will influence INmune Bio’s interactions with the EMA and FDA for future submissions.
- Clinical Strategy
- Whether INmune Bio can successfully incorporate MHRA’s endpoint recommendations into its confirmatory Phase 3 program.
- Market Timing
- The pace at which INmune Bio can transition from conditional approval to full marketing authorization in the UK and other regions.
Related topics